Expert Opinion on Biological Therapy

Papers
(The H4-Index of Expert Opinion on Biological Therapy is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli76
Biosimilars and access to biologic therapy in immune-mediated diseases59
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol58
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males54
The endosomal-lysosomal system in ADC design and cancer therapy53
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases43
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions41
Aflibercept biosimilars – so near, yet so far32
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?32
IL-4/IL-13 targeted biologics in atopic dermatitis: is their use safe in oncologic patients?31
Antibody drug conjugates for glioblastoma: current progress towards clinical use31
Bispecific antibody combination regimens for B-cell non-Hodgkin’s lymphomas28
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences28
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era28
Signaling new therapeutic opportunities: cytokines in prostate cancer27
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden26
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)26
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway26
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma25
Correction25
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?24
Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials23
Long-acting delivery and therapies for neovascular age-related macular degeneration23
0.1386411190033